NEWS & EVENTS

Latest news and upcoming events

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment
16 Sep 2025

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

Upcoming events

  • BioCapital Europe 2026
    3 March - 4 March , 2026
    Amsterdam

    download

  • 19TH​ ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM
    4 - 5 March, 2026
    Zurich

    download

  • BioEurope Spring 2026
    23 - 25 March, 2025
    Lisbon

    download

  • LSX World Congress Europe 2026
    25 - 26 March, 2026
    Lisbon

    download
SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy<
09 Feb 2026

SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy

The NYRVANA first-in-human trial is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology<
09 Feb 2026

Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology

Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology
Telescope Biotech Fund cierra 2025 como el Fondo de Inversión Libre más rentable del año en España<
20 Jan 2026

Telescope Biotech Fund cierra 2025 como el Fondo de Inversión Libre más rentable del año en España

El vehículo, gestionado por Andbank Wealth Management y asesorado por Ysios Capital, registra un retorno neto del 52,5% desde su lanzamiento en febrero de 2025.
Inbiomotion’s MAF Test® included in 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer, further supporting its clinical utility<
15 Jan 2026

Inbiomotion’s MAF Test® included in 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer, further supporting its clinical utility

A key consensus document guiding clinical decision-making in Spain and referenced internationally.
VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization<
08 Jan 2026

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

VMX‑C001 builds on strong regulatory momentum, including FDA Fast Track Designation and PMDA Phase 1 waiver, as it progresses toward a global Phase 3 trial

SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease<
08 Jan 2026

SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

First dose-expansion patient successfully received SB-007
SpliceBio Appoints Don Munoz as Chief Financial Officer<
06 Jan 2026

SpliceBio Appoints Don Munoz as Chief Financial Officer

His leadership will be instrumental as we enter our next stages of development and position SpliceBio for long-term value creation.
Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market<
02 Dec 2025

Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market

European market approval and US pre-market approval of aXess expected in 2026
Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting<
07 Nov 2025

Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting

Potravitug was well tolerated, with no treatment related serious adverse events reported
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025<
07 Nov 2025

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

The presentations at ASN Kidney Week demonstrated the breadth and strength of lorundrostat’s clinical program.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Buying a Replica Rolex is easy and secure. Our seamless process ensures your watch arrives quickly and safely, backed by our satisfaction guarantee.